Treatment with AC Pulsed Electromagnetic Fields Improves the Response to Levodopa in Parkinson's Disease

References

• Antolin I., Rodriguez C., Sainz R. M., Mayo J., Uria H., Kotler M. L., Rodriguez-Colunga M. J., Tolivia D., Menedez-Pelaez A. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. Faseb Journal 1996; 10: 882–890
   PubMed Web of Science ®Google Scholar
• Bawin S. M., Adey W. R. Sensitivity of calcium binding in cerebral tissue to weak environmental electric fields oscillating at low frequency. Proceedings of the National Academy of Sciences, USA 1976; 73: 1999–2003
   PubMed Web of Science ®Google Scholar
• Barlow-Walden L. R., Reiter R. J., Abe M., Pablos M., Menendez-Pelaez A., Chen L. D., Poeggeler B. Melatonin stimulates brain glutathione peroxidase activity. Neurochemistry International 1995; 26: 497–502
   PubMed Web of Science ®Google Scholar
• Bernheimer H., Birkmayer W., Hornykiewicz O. Verteilung des 5-hydroxytryptamins (Serotonin) in Gehirn des Menschen und sein Verhalten bein Patienten mit Parkinson Syndrome. Klinische Wochenschrift 1961; 39: 1056–1059
   PubMedGoogle Scholar
• Blackman C. F. Stimulation of brain tissue in vitro by extremely low frequency, low intensity, sinusoidal electromagnetic fields. Electromagnetic fields and neurobehavioral function, M. E. O'connor, R. H. Lovely. Alan R. Liss, New York 1988
   Google Scholar
• Bradbury A. J., Kelly M. E., Smith J. A. Melatonin Melatonin action in the mid-brain can regulate dopamine function both behaviourally and biochemically. The pineal gland: endocrine aspects, G. M. Brown, S. D. Wainwright. Pergamon Press, Oxford 1985; 327–332
   Google Scholar
• Cotzias G. C., Tang L. C., Miller S. T., Ginos J. Z. Melatonin and abnormal movement induced by L-dopa in mice. Science 1971; 173: 450–452
   PubMed Web of Science ®Google Scholar
• Davidson D. L. W., Yates C. M., Mawdsley C., Pullar I. A., Wilson H. CSF studies on the relationship between dopamine and 5-hydroxytryptamine in Parkinsonism and other movement disorders. Journal of Neurology Neurosurgery and Psychiatry 1977; 40: 1136–1141
   PubMed Web of Science ®Google Scholar
• Dray A. Serotonin in the basal ganglia: functions and interactions with other neuronal pathways. Journal of Physiology, (Paris) 1981; 77: 393–403
   PubMedGoogle Scholar
• Ehringer H., Hornykiewicz O. Verteilung von Noradrenalin und Dopamine (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalar Systems. Wien Klinischer Wochenschrift 1960; 38: 1236–1239
   Web of Science ®Google Scholar
• Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiological aspects. Movement disorders, C. D. Marsden, S. Fahn. Butterworths Scientific, London 1981; 123–145
   Google Scholar
• Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Annals of Neurology 1992; 32: 804–812
   PubMed Web of Science ®Google Scholar
• Fahn S., Libsch L. R., Cutler R. W. Monoamines in the human neostriatum: Topographic distribution in normals in Parkinson's disease and their role in akinesia, rigidity, chorea and tremor. Journal of Neurological Sciences 1971; 14: 427–455
   PubMed Web of Science ®Google Scholar
• Gancher S. T., Nutt J. G. Diurnal responsiveness to apomorphine. Neurology 1987; 37: 1250–1253
   PubMed Web of Science ®Google Scholar
• Gershanik O. S., Heikkila R. E., Duvoisin R. C. The role of serotonin neurons in the action of L-dopa in an animal model of Parkinsonism. Neurology 1979; 29: 553, (suppl)
   Web of Science ®Google Scholar
• Giusti P., Gusella M., Lipartiti M., Milani D., Zhu W., Vicini S., Manev H. Melatonin protects primary cultures of cerebellar granule neurons from kainate but not from N-Methyl-D-Aspartate excitotoxicity. Experimental Neurology 1995; 131: 39–46
   PubMed Web of Science ®Google Scholar
• Hoehn M. M., Yahr M. D. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427–442
   PubMed Web of Science ®Google Scholar
• Jaffe R. A., Laszewski B. L., Carr D. B., Phillips R. D. Chronic exposure to a 60-Hz electric field: effects on synaptic transmission and peripheral nerve function in the rat. Bioelectromagnetics 1980; 1: 131–147
   PubMedGoogle Scholar
• Jolley W. B., Hinshaw D. B., Knierim K., Hinshaw D. B. Magnetic field effects on calcium efflux and insulin secretion in isolated rabbit iselts of langerhans. Bioelectromagnetics 1983; 4: 103–106
   PubMed Web of Science ®Google Scholar
• Kaczmarek L., Adey W. Weak electric gradient change ionic and transmitter fluxes in cortex. Brain Research 1974; 66: 537–540
   Web of Science ®Google Scholar
• Karabakhtsian R., Broude N., Shalts N., Kochlatyi S., Goodman R., Henderson A. S. Calcium is necessary in the cell response to EM fields. Febs Letters 1994; 349: 1–6
   PubMed Web of Science ®Google Scholar
• Manev H., Uz T., Kharlamov A., Joo J. Y. Increased brain damage after stroke or exci-totoxic seizures in melatonin-deficient rats. Faseb Journal 1996; 10: 1546–1551
   PubMed Web of Science ®Google Scholar
• Marsden C. D., Parkes J. D. On-off effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976; 1: 292–296
   PubMed Web of Science ®Google Scholar
• Marsden C. D., Parkes J. D. On and off variability and response swings in Parkinson's disease. Research progress in parkinson's disease, F. C. Rose, R. Capildeo. Pitman Medical, Kent 1980; 265–274
   Google Scholar
• Marsden C. D., Parkes J., Quinn N. Fluctuations of disability in Parkinson's disease: clinical aspects. Movement disorders, C. D. Marsden, S. Fahn. Butterworths Scientific, London 1981; 96–122
   Google Scholar
• Meara J. Serotonin and the extrapyramidal system- a neurological perspective. Hitman Psychopharmacology 1996; 11: S95–S102
   Web of Science ®Google Scholar
• Miguez J. M., Martin F., Aldegunde M. Long-term pinealectomy alters hypothalamic serotonin metabolism in the rat. Journal of Pineal Research 1991; 11: 75–79
   PubMed Web of Science ®Google Scholar
• Miguez J. M., Martin F. J., Aldegunde M. Effects of single doses and daily melatonin treatments on serotonin metabolism in rat brain regions. Journal of Pineal Research 1994; 17: 170–176
   PubMed Web of Science ®Google Scholar
• Nausieda P., Weiner W. J., Kaplan L. R., Weber S., Klawans H. L. sleep disruption in the course of levodopa therapy: an early feature of the levodopa psychosis. Clinical Neuropharmacology 1982; 5: 183–194
   PubMed Web of Science ®Google Scholar
• Nausieda P., Glantz R., Weber S., Baum R., Klawans H. L. Psychiatric complications of levodopa therapy of Parkinson's disease. Advances in neurology, R. G. Hassler, J. F. Christ. Raven Press, New York 1984; Vol. 40: 271–277
   Google Scholar
• Olanow C. W. A 61-year-old man with Parkinson's disease. Journal of the American Medical Association 1996; 275: 716–722
   Web of Science ®Google Scholar
• Reiter R. J. Oxidative processes and antioxidative defense mechanism in the aging brain. Faseb Journal 1995; 9: 526–533
   PubMed Web of Science ®Google Scholar
• Riederer P. L-dopa competes with tyrosine and tryptophan for human brain uptake. Nutrition & Metabolism 1980; 24: 417–423
   Web of Science ®Google Scholar
• Rosen A. D. Magnetic field influence on acetylcholine release at the neuromuscular junction. American Journal of Physiology 1992; 262: C1418–C1422
   PubMed Web of Science ®Google Scholar
• Rudolph K., Wirz-Justice A., Krauchi K., Feer H. Static magnetic fields decrease nocturnal pineal cAMP in the rat. Brain Research 1988; 446: 159–160
   PubMed Web of Science ®Google Scholar
• Sandyk R. Weak magnetic fields as a novel therapeutic modality in Parkinson's disease. International Journal of Neuroscience 1992a; 66: 1–15
   PubMed Web of Science ®Google Scholar
• Sandyk R. Weak magnetic fields in the treatment of Parkinson's disease with the “on-off phenomenon.”. International Journal of Neitroscience 1992b; 66: 97–106
   PubMed Web of Science ®Google Scholar
• Sandyk R. Magnetic fields in the therapy of Parkinsonism. International Journal of Neuroscience 1992c; 66: 209–235
   PubMed Web of Science ®Google Scholar
• Sandyk R. A drug naive Parkinsonian patient successfully treated with electromagnetic fields. International Journal of Neuroscience 1994a; 79: 99–110
   PubMed Web of Science ®Google Scholar
• Sandyk R. Treatment of Parkinson's disease with magnetic Fields reduces the requirement for antiparkinsonian medications. International Journal of Neitroscience 1994b; 74: 191–201
   PubMedGoogle Scholar
• Sandyk R. Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields. International Journal of Neuroscience 1996; 85: 111–124
   PubMed Web of Science ®Google Scholar
• Sandyk R., Derpapas K. The effects of external picotesla range magnetic fields on the EEG in Parkinson's disease. International Journal of Neuroscience 1993a; 70: 85–96
   PubMedGoogle Scholar
• Sandyk R., Derpapas K. Further observations on the unique efficacy of picotesla magnetic fields in Parkinson's disease. International Journal of Neuroscience 1993b; 69: 167–183
   PubMedGoogle Scholar
• Sawada M., Nagatsu T., Nagtsu I., Ito K., Lizuka R., Kondo T., Narabayashi H. Tryptophan hydroxylase activity in the brains of controls and Parkinsonian patients. Journal of Neural Transmission 1985; 62: 107–115
   PubMed Web of Science ®Google Scholar
• Scatton B., Javoy-Agid F., Rouquier L., Dubois B., Agid Y. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Research 1983; 275: 321–328
   PubMed Web of Science ®Google Scholar
• Scatton B., Dennis T., L'heureux R., Monfort J. C., Duyckaerts C., Javoy-Agid F. Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients. Brain Research 1986; 380: 181–185
   PubMed Web of Science ®Google Scholar
• Semm P. Pineal function in mammals and birds is altered by earth-strength magnetic fields. Electromagnetic fields and circadian rhythmicity, M. C. Moore-Ede, S. S. Campbell, R. J. Reiter. Birkhauser, Boston 1992; 53–62
   Google Scholar
• Semm P., Schneider T., Vollrath L. Effects of an earth-strength magnetic field on electrical activity of pineal cells. Nature 1980; 288: 607–608
   PubMed Web of Science ®Google Scholar
• Tohgi H., Abe T., Takahashi S., Takahashi J., Hamato H. Alteration in the concentration of serotonergic and dopaminergic substances in the cerebrospinal fluid of patients with Parkinson's disease, and their changes after L-dopa administration. Neuroscience Letters 1993; 159: 135–138
   PubMed Web of Science ®Google Scholar
• Trabulsi R., Pawlowski B., Wieraszko A. The influence of steady magnetic fields on the mouse hippocampal evoked potentials in vitro. Brain Research 1996; 728: 135–139
   PubMed Web of Science ®Google Scholar
• Walleczek J. Electromagnetic field effect on cells of the immune system: the role of calcium signalling. Faseb Journal 1992; 6: 3177–3185
   PubMed Web of Science ®Google Scholar
• Welker H. A., Semm P., Willig R. P., Commentz J. C., Wiltschko W., Vollrath L. Effects of an artificial magnetic field on serotonin N-acetyltransferase activity and melatonin content of the rat pineal gland. Experimental Brain Research 1983; 50: 426–432
   PubMed Web of Science ®Google Scholar
• Wilson B. W., Stevens R. G., Anderson L. E. Neuroendocrine mediated effects of electromagnetic field exposure: possible role of the pineal gland. Life Sciences 1989; 45: 1319–1332
   PubMed Web of Science ®Google Scholar